Emerging in the arena of obesity treatment, retatrutide presents a unique strategy. Different from many existing medications, retatrutide functions as a double agonist, at once affecting both GLP peptide-1 (GLP-1) and glucose-responsive insulinotropic hormone (GIP) binding sites. The concurrent stimulation promotes various helpful effects, such as … Read More